Nxera Pharma Co (Nxera Pharma Co) Debt-to-Equity : 1.11 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co Debt-to-Equity?

Nxera Pharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $47.04 Mil. Nxera Pharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $466.73 Mil. Nxera Pharma Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $464.02 Mil. Nxera Pharma Co's debt to equity for the quarter that ended in Dec. 2023 was 1.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nxera Pharma Co's Debt-to-Equity or its related term are showing as below:

SOLTF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.38 Max: 1.36
Current: 1.11

During the past 13 years, the highest Debt-to-Equity Ratio of Nxera Pharma Co was 1.36. The lowest was 0.04. And the median was 0.38.

SOLTF's Debt-to-Equity is ranked worse than
88.99% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs SOLTF: 1.11

Nxera Pharma Co Debt-to-Equity Historical Data

The historical data trend for Nxera Pharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Debt-to-Equity Chart

Nxera Pharma Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.32

0.51

1.11

Nxera Pharma Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.51	0.51	0.49	1.27	1.11

Competitive Comparison of Nxera Pharma Co's Debt-to-Equity

For the Biotechnology subindustry, Nxera Pharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Debt-to-Equity falls into.

Nxera Pharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nxera Pharma Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(47.041	+	466.727)	/	464.018
	=	1.11

Nxera Pharma Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(47.041	+	466.727)	/	464.018
	=	1.11

Nxera Pharma Co (OTCPK:SOLTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nxera Pharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co (Nxera Pharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

4565:Japan JSS:Germany

Address

2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083

Website

http://www.sosei.com

Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.